Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from SoftOx Solutions AS ( (DE:6FV) ) is now available.
SoftOx Solutions AS has announced a breakthrough in the stability of hypochlorous acid (HOCl), a core component of its inhaled therapy for cystic fibrosis. This advancement is pivotal for the company’s inhaled SIS program and could lead to broader applications, including biological defense and treatment of non-CF bronchiectasis, with a proof-of-concept trial scheduled for Q1 2026.
More about SoftOx Solutions AS
SoftOx Solutions AS is a clinical-stage pharmaceutical company listed on Euronext Growth Oslo, focusing on developing highly effective pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. Their technology is developed in collaboration with leading Nordic research institutes.
Average Trading Volume: 20,626,568
Current Market Cap: NOK188.1M
See more data about 6FV stock on TipRanks’ Stock Analysis page.